Affiliation: University of Maryland
- The evolving role of postoperative adjuvant radiation therapy for pancreatic cancerMichael C Garofalo
Department of Radiation Oncology, University of Maryland at Baltimore, 22 South Green Street, Baltimore, MD 21201, USA
Surg Oncol Clin N Am 13:589-604, viii. 2004..Implications of the recently completed intergroup study are discussed, modern radiation therapy delivery techniques are reviewed, and suggestions for future trials are made...
- The case for adjuvant chemoradiation for pancreatic cancerMichael Garofalo
Department of Radiation Oncology, University of Maryland Medical Center, 22 S Greene Street, Baltimore, MD 21201, USA
Best Pract Res Clin Gastroenterol 20:403-16. 2006..Modern radiotherapy delivery techniques will also be discussed and future trial designs suggested...
- Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancersSusannah Yovino
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Int J Radiat Oncol Biol Phys 79:158-62. 2011..Whether these improved dose distributions are associated with decreased toxicity when compared with conventional three-dimensional treatment remains a subject of investigation...
- Linking the human response to unplanned radiation and treatment to the nonhuman primate response to controlled radiation and treatmentHarald Dörr
Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, Germany University of Maryland, School of Medicine, Department of Radiation Oncology, Baltimore, MD U S Food and Drug Administration FDA, Silver Spring, MD
Health Phys 106:129-34. 2014....
- Predicting unresectability in pancreatic cancer patients: the additive effects of CT and endoscopic ultrasoundSusannah Yovino
Department of Radiation Oncology, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21201, USA
J Gastrointest Surg 11:36-42. 2007..A standardized method for predicting unresectability in pancreatic cancer has not been defined. We propose a system using CT and endoscopic ultrasound (EUS) to assess patients for unresectable pancreatic cancers...
- The prolonged gastrointestinal syndrome in rhesus macaques: the relationship between gastrointestinal, hematopoietic, and delayed multi-organ sequelae following acute, potentially lethal, partial-body irradiationThomas J MacVittie
Department of Radiation Oncology, University of Maryland, School of Medicine, Baltimore, MD 21201, USA
Health Phys 103:427-53. 2012..Specific and multi-organ medical countermeasures can be assessed for efficacy and interaction during the concomitant evolution of acute and delayed key organ-specific subsyndromes...
- Radiation oncology emergenciesYoung Kwok
Department of Radiation Oncology, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21201, USA
Hematol Oncol Clin North Am 20:505-22. 2006..When radiation therapy is used, the total dose and fractionation schedule should be tailored to the disease setting and life expectancy of the patient...
- Primary MALT lymphoma of the gallbladder. Case reportMatthew Koshy
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
J Gastrointestin Liver Dis 17:207-10. 2008..When the disease is localized to the gallbladder, primary MALT lymphomas of the gallbladder carry an excellent prognosis, and surgical resection is curative in the majority of cases...
- Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigmWilliam F Regine
Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
Int J Radiat Oncol Biol Phys 68:172-7. 2007..To determine the maximum tolerated dose of upper abdominal low-dose fractionated radiotherapy (<1.0 Gy per fraction) given in combination with, and as a chemopotentiator for, gemcitabine...
- On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancerMichael C Garofalo
Ann Surg 244:332-3; author reply 333. 2006
- Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directionsMichael T Milano
Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
Int J Oncol 28:1141-51. 2006..Building on the present clinical experience, future directions include more directed efforts at reducing toxicity, with better planning software and planning techniques...
- Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcomeMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 59:445-53. 2004..To assess the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) in pancreatic and bile duct (cholangiocarcinoma) malignancies...
- Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive reviewJohnny Kao
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA
Cancer Treat Rev 29:21-30. 2003..The results of reirradiation in recurrent head and neck cancer and the prognostic factors predicting outcome in this patient population are reviewed...
- Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancerMichael C Garofalo
University of Chicago, Department of Radiation and Cellular Oncology, Chicago, Illinois 60637, USA
Curr Opin Oncol 14:330-3. 2002..This article provides a rationale for management and reviews recent results of reirradiation...